Download File - JOHN J. HADDAD, Ph.D.

More documents

Recommendations

Info

Table 1 Examples of Preclinical Activity in Rodents Treated with Autologous Cancer Vaccines: Effect of Tumor Burden on Outcome (Continued ) Cancer type Vaccine type Efficacy Disease settings Preclinical Models and Clinical Situation 35 Early: treatment started 1 day after tumor challenge Moderately advanced: treatment started 7 days after tumor challenge Advanced: treatment started 14 days after tumor 100% complete tumor rejection (cure) in early setting vs. 60% cure in moderately advanced disease setting and 30% cure in advanced disease setting (14) Breast IL-2–transduced tumor cells challenge Early: treatment started 6 days after tumor challenge Advanced: treatment started 9 days after tumor challenge Minimal disease: primary tumor surgically removed prior to start of vaccination, yet still bore second tumor at distal site Bulky disease: no surgical resection and thus bore primary and secondary tumor at time of vaccination Early: treatment started 3 days after tumor challenge Moderately advanced: treatment started 7–10 days after tumor challenge Early: treatment started 3 days after tumor challenge Moderately advanced: treatment started 10 days after tumor challenge Advanced: treatment started 17 days after tumor challenge 70% of mice alive at day 200 (end of study) in early setting compared with 0% in control group vs. 20% alive in advanced disease (15) Kidney IL-4–transduced tumor cells Significant reduction in rate of tumor growth in minimal disease setting vs. no effect of vaccination in bulky disease setting (16) Mesothelioma B7-1–transduced tumor cells 87% complete tumor rejection (cure) in early setting vs. 0% cure in moderately advanced disease setting (17) Myeloma TNF-a–transduced and B7-1–transduced tumor cells 83% of mice alive at day 71 (end of study) in early setting, 34% alive in moderately advanced disease setting, and 0% alive in advanced disease setting (18) Fibrosarcoma IFN-g–transduced and B7-1–transduced tumor cells (Continued)
36 Levey Table 1 Examples of Preclinical Activity in Rodents Treated with Autologous Cancer Vaccines: Effect of Tumor Burden on Outcome (Continued ) Cancer type Vaccine type Efficacy Disease settings Early: treatment started 10 days after tumor challenge Advanced: treatment started 20 days after tumor 33% of mice alive at end of study (>180 days) in early setting compared with 0% in control group vs. 13% alive in advanced disease (19) Liver Tumor cells mixed with BCG challenge Early: treatment started 1 day after tumor challenge Advanced: treatment started 4 days after tumor challenge Early: treatment started same day as tumor challenge Advanced: treatment started 3 days after tumor challenge 40% of mice alive at end of study (>180 days) in early setting compared with 0% in control group vs. 0% alive in advanced disease (20) Liver Tumor cells mixed with BCG 23% of mice alive at end of study (>60 days) in early setting compared with 0% in control group vs. 0% alive in advanced disease (21) Lymphoma Adenovirus-encoding idiotype þ cyclophosphamide Abbreviations: HSPPC-96, heat shock protein–peptide complex; GM-CSF, granulocyte macrophage colony–stimulating factor; IL-12, interleukin 12; IL-2, interleukin 2; IL-4, interleukin 4; TNF-a, tumor necrosis factor a; IFN-g, interferon g; BCG, bacille Calmette–Guérin.
Page 1 and 2: Translational Medicine Series 6 Can
Page 3 and 4: TRANSLATIONAL MEDICINE SERIES 1. Pr
Page 5 and 6: Informa Healthcare USA, Inc. 52 Van
Page 8 and 9: Preface Throughout the last 20 year
Page 10 and 11: Preface vii Table 1 A Diverse Techn
Page 12 and 13: Preface . . . . v Contributors . .
Page 14 and 15: Contributors Pedro Alves Ludwig Ins
Page 16 and 17: 1 Factoring in Antigen Processing i
Page 18 and 19: Factoring in Antigen Processing in
Page 46 and 47: 2 Outlining the Gap Between Preclin
Page 48 and 49: Preclinical Models and Clinical Sit
Page 68: Preclinical Models and Clinical Sit
Page 71 and 72: 56 Srinivasan disease agents. Garda
Page 73 and 74: 58 Srinivasan expressing various kn
Page 75 and 76: 60 Srinivasan The above-mentioned a
Page 77 and 78: 62 Srinivasan (69). In another stud
Page 79 and 80: 64 Srinivasan patients with prostat
Page 81 and 82: 66 Srinivasan 33. Salgia R, Lynch T
Page 83 and 84: 68 Srinivasan 67. Werness BA, Levin
Page 85 and 86: 70 Teofilovici and Wentworth In 190
Page 87 and 88: 72 Teofilovici and Wentworth conduc
Page 89 and 90: 74 Teofilovici and Wentworth Lipono
Page 91 and 92: 76 Teofilovici and Wentworth (best
Page 93 and 94: 78 Teofilovici and Wentworth nature
Page 95 and 96: 80 Teofilovici and Wentworth In the
Page 97 and 98: 82 Teofilovici and Wentworth 17. Ba
Page 99 and 100: 84 Luptrawan et al. Dendritic cells
Page 101 and 102:
86 Luptrawan et al. of cancer cells
Page 103 and 104:
88 Luptrawan et al. NK cells can ki
Page 105 and 106:
90 Luptrawan et al. Figure 2 Repres
Page 107 and 108:
92 Luptrawan et al. state (50). Pat
Page 109 and 110:
94 Luptrawan et al. ability of TIL
Page 111 and 112:
96 Luptrawan et al. Figure 4 Drug s
Page 113 and 114:
98 Luptrawan et al. Figure 6 Tumor
Page 115 and 116:
Table 1 Summary of results of phase
Page 117 and 118:
102 Luptrawan et al. Table 1 Summar
Page 119 and 120:
104 Luptrawan et al. antigens (84,8
Page 121 and 122:
106 Luptrawan et al. 30. Ranges GE,
Page 123 and 124:
108 Luptrawan et al. 66. Dunn GP, B
Page 125 and 126:
110 Schroter and Minev proteins (2,
Page 127 and 128:
112 Schroter and Minev tumor-challe
Page 129 and 130:
114 Schroter and Minev Table 1 Inve
Page 131 and 132:
116 Schroter and Minev Table 1 Inve
Page 133 and 134:
118 Schroter and Minev demonstrated
Page 135 and 136:
120 Schroter and Minev loaded MART-
Page 137 and 138:
122 Schroter and Minev illustrate t
Page 139 and 140:
124 Schroter and Minev 4. Heemels M
Page 141 and 142:
126 Schroter and Minev 42. Minev BR
Page 143 and 144:
128 Schroter and Minev 74. Restifo
Page 146 and 147:
7 Multimodality Immunization Approa
Page 148 and 149:
Multimodality Immunization Approach
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Figure 5.1 Immunohistochemical char
Page 164 and 165:
Figure 8.5 A schematic representati
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
8 Bidirectional Bedside Lab Bench P
Page 172 and 173:
Development of Novel Immunotherapeu
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
9 Diagnostic Approaches for Selecti
Page 202 and 203:
Diagnostic Approaches to Maximize T
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222:
Page 225 and 226:
206 Index Antigenic peptides degrad
Page 227 and 228:
208 Index Chromogens, enzymatic act
Page 229 and 230:
210 Index Freund’s adjuvants. See
Page 231 and 232:
212 Index Langerhans cells, 133, 13
Page 233 and 234:
214 Index [Peptide vaccines] invest
Page 235 and 236:
216 Index TCRL. See TCR-like immuno
Page 238:
Oncology and Immunology about the b
show all

Download File - JOHN J. HADDAD, Ph.D.

Create successful ePaper yourself

Delete template?

Save as template?